Αποτελέσματα Αναζήτησης
EXCLUSIONS: Pregnancy. Significant cardiovascular disease and/or LVEF less than 50%; if initial reading is less than 50%, physician may consider repeating for validity, or assessing LVEF by the other modality, e.g. echocardiogram instead of MUGA. Known hypersensitivity to E. coli derived products.
This protocol is part of the AC-TH regimen: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Link to Breast adjuvant AC-TH overview; Link to Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly; Drug status: Docetaxel is on the PBS general schedule. Trastuzumab is PBS authority
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T) described in regimen NCCP-00485 INDICATIONS FOR USE:
AC is a combination of two chemotherapy drugs used to treat breast cancer. It takes its name from the initials of these drugs: doxorubicin (also known as Adriamycin) cyclophosphamide. under the arm. Sometimes it’s used in combination with other a. ti-cancer drugs. Chemotherapy is given to reduce the risk of breast cancer return.
G-CSF support (using standard or pegylated form) is required with all cycles of dose dense DOXOrubicin and cycloPHOSphamide. Facilities to treat anaphylaxis MUST be present when the systemic anti-cancer therapy (SACT) is administered.
This treatment regimen consists of two parts: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Breast neoadjuvant/adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly. Breast adjuvant TH (DOCEtaxel and trastuzumab) three weekly.
7 Δεκ 2022 · The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with breast cancer, both in the adjuvant and neoadjuvant settings.
